23:27 , Jul 11, 2019 |  BC Extra  |  Company News

July 11 Company Quick Takes: Ono gains Asia rights to Forty Seven's mAb; plus Aimmune, Passage-Paragon and more

Ono gets local rights to Forty Seven's mAb  Forty Seven Inc. (NASDAQ:FTSV) granted Ono Pharmaceutical Co. Ltd. (Tokyo:4528) exclusive rights in certain Asian territories to 5F9, a humanized mAb targeting CD47, as monotherapy or in...
00:47 , Jun 29, 2019 |  BioCentury  |  Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

While the typical summer lull means fewer catalysts in the third quarter, investors will be keeping a close eye on launches of new modality drugs. Of special interest to multiple buysiders is the launch of...
23:48 , Jun 28, 2019 |  BC Extra  |  Company News

June 28 Company Quick Takes: FDA approves Pfizer's biosimilar of Avastin; plus Aimmune, PeptiDream, Novartis and Just/Teva

Pfizer gets second FDA-approved biosimilar with Zirabev approval  FDA approved Zirabev bevacizumab-bvzr from Pfizer Inc. (NYSE:PFE) to treat metastatic colorectal cancer; unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell long cancer; recurrent glioblastoma; metastatic...
22:03 , Jun 26, 2019 |  BC Extra  |  Company News

June 26 Company Quick Takes: Dupixent approved for nasal polyps; plus Ono/Rafael, Oxford/Santen and more

FDA approves Regeneron's Dupixent in nasal polyps  FDA approved Dupixent dupilumab from Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) to treat chronic rhinosinusitis with nasal polyps. Dupixent is the first drug approved for the indication (see "Phase III...
12:31 , Jun 13, 2019 |  BioCentury  |  Finance

With $76M series B, BlackThorn looks to build out neurobehavioral platform

BlackThorn has amassed a $76 million series B round from investors who are banking on the potential of its PathFinder platform to circumvent the issue of patient heterogeneity in neurobehavioral disorders. New investors Polaris Partners,...
23:50 , Jun 11, 2019 |  BC Extra  |  Company News

June 11 Company Quick Takes: Genmab, Janssen together again on CD38; plus GT Apeiron’s launch; BiomX, Aimmune, Keytruda

Genmab, Janssen partner on next-gen CD38 mAb Genmab A/S (CSE:GEN; Pink:GMXAY) granted Janssen Biotech Inc. an option to HexaBody-CD38, building on the companies' collaboration on multiple myeloma CD38 mAb Darzalex daratumumab. Genmab will fund R&D...
21:13 , May 16, 2019 |  BC Extra  |  Company News

May 16 Company Quick Takes: Iconic oncology deals; plus Zymeworks-GSK, Aimmune and more

Iconic in pair of deals to develop lead oncology program  Iconic Therapeutics Inc. (South San Francisco, Calif.) granted Exelixis Inc. (NASDAQ:EXEL) an option to license ICON-2 for $7.5 million up front and funding for preclinical...
18:06 , Apr 10, 2019 |  BC Extra  |  Company News

ICER draft report: Aimmune's peanut allergy therapy cost effective, DBV's falls short

ICER thinks Aimmune's peanut allergy therapy AR101 could be cost effective but found that DBV’s Viaskin Peanut exceeded standard cost-effectiveness ratios, according to a draft evidence report published Tuesday. The institute said both therapies may...
00:06 , Apr 6, 2019 |  BioCentury  |  Finance

Big caps under pressure

Biogen’s fall in the wake of its decision to discontinue late-stage trials of Alzheimer’s therapy aducanumab is yet another reminder that large caps are in dire need of new pipeline products, and could serve as...
20:02 , Mar 25, 2019 |  BC Extra  |  Clinical News

Aimmune on track for EU submission of peanut allergy therapy

A week after Aimmune said an FDA decision on approval of its peanut allergy therapy may come a month late, the company said Monday its timeline for an MAA submission remains on schedule following a...